Pfizer seeks U.S. approval for COVID vaccine booster
26 Aug 2021
Pfizer (NYSE:PFE) is trading up 0.24% at 47.50
Pfizer Inc on Wednesday said a booster dose of its two-shot COVID-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the company seeks U.S. regulatory approval for a third injection.
The drugmaker and its German partner BioNTech SE (NASDAQ:BNTX) aim to complete the submission for use of booster shots in people aged 16 and over by the end of this week.
The U.S. government has said it was gearing up to roll out the third shot of vaccines from both Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc from mid-September to Americans who had their initial course more than eight months ago if the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention decide that boosters are needed.
That eight-month gap is likely to be narrowed to six months, the Wall Street Journal reported on Wednesday.
A committee of outside advisors to the CDC is scheduled to meet on Monday to review clinical data.
Pfizer said 306 people given a third dose of its vaccine between five and eight months after their second shot showed levels of neutralizing antibodies that were 3.3 times the levels seen after their second shot.
On technical fronts Pfizer (NYSE:PFE) RSI stood at 37.22 and currently stock is trading below all Moving Average. So, SELL position can be taken with following target and stoploss:
TRADE SIGNAL – : Pfizer (NYSE:PFE) – SELL: 47.32, TARGET: 46.90, STOP LOSS : 47.78